German neuroblastoma mass screening study at 12 months of age: statistical aspects and preliminary results
✍ Scribed by Schilling, Freimut H.; Spix, Claudia; Berthold, Frank; Erttmann, Rudolf; Hero, Barbara; Michaelis, Jörg; Sander, Johannes; Tafese, Tatjana; Treuner, Jörn
- Publisher
- John Wiley and Sons
- Year
- 1998
- Tongue
- English
- Weight
- 114 KB
- Volume
- 31
- Category
- Article
- ISSN
- 0098-1532
No coin nor oath required. For personal study only.
✦ Synopsis
Background. The question of whether screening for neuroblastoma (NB) results in a substantial improvement of the prognosis of the disease is still open. All data, including those of the European pilot studies, indicate the possibility of overdiagnosis in the case of possibly spontaneously regressing NBs if the screening is performed before 6 months of age. Based on two pilot studies (at 6 and 12 months), an epidemiological approach to evaluate NB screening at 12 months of age was started in May 1995. Procedure. Extensive statistical considerations about the assessment of a the sample size and overdiagnosis have been made in preparing the study design of the controlled and population-based screening validation study. Screening takes place in 6 of the 16 German states, with the remaining serving as controls. A minimum of 1,250,000 children will be tested during the study period and the same number will be followed without screening. The German Children's Cancer Registry enables a nearly complete follow-up of all NB patients in Germany. By postponing the procedure to a later age, it should be possible to control the phenomenon of overdiagnosis at a reasonable level. Results. Until December 31, 1997, 644,396 children were examined and 67 cases of NB detected preclinically (detection rate: 10.4/100,000). Within this cohort, three false negative cases were found. One child with stage 2B neuroblastoma died of a surgical complication. The compliance rate in this study is 65% and thus lower than expected. Preliminary results on overdiagnosis will be available in late 1998. Med.